| |
|
|
|
|
|
|
|
New Perspectives on
Transporters in Drug Discovery and Development: ADME and Beyond
Thursday 23rd June 2011
Millennium
Gloucester Hotel & Conference Centre London Kensington |
|
Programme: |
|
09.00 |
Arrival, Registration
and Coffee |
|
|
|
Session 1 : Introducing Drug Transporters. Chair - Phil Jeffery |
|
|
|
|
10.00
|
Paul Dobson, University of Sheffield
The
central importance of transporters in drug uptake. |
|
10.45 |
Joseph Polli, GlaxoSmithKline, USA
What’s all the
flux about? Interpretation and application of the International
Transporter Consortium whitepaper and Draft EMA Guidance. |
|
11.30 |
Glynis Nicholls, AstraZeneca, UK
Human transporters
and relevance of preclinical models from a regulatory perspective. |
|
|
|
|
12.15 |
Lunch |
|
|
|
|
Session 2 : Drug Transporters as Targets in Modulating Disease. Chair -
Jack Allen |
|
|
|
|
13.30 |
Scott Allen, University of Sheffield
Mitochondrial
dysfunction in Motor Neurone Disease- a potential problem? |
|
14.15 |
Simone Stahl, AstraZeneca, UK
The role of hepatobiliary transporters in drug-induced liver injury. |
|
|
|
|
15.00 |
Tea |
|
|
|
|
Session 3 : Drug Transporters: Challenges for ADME. Chair - Paul
Fish |
|
|
|
|
15.30 |
Hannah Jones, Pfizer, UK
OATP
transporters in hepatic clearance, a case history. |
|
16.15 |
Cynthia Bosquillon, University of
Nottingham
Drug
transporters in the lung. |
|
|
|
|
17.00 |
Close |
|
|
|
Back
to Menu
|
|
|
|
|
|
|
